Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle propertiesArticle Published on 2022-05-102022-10-04 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 신약개발, [키워드] acute lung injury acute respiratory syndrome administration alleviate anionic anti-inflammatory activity antiviral activity Bioavailability Blood cationic Cell chitosan. circulation coronavirus coronavirus disease COVID-19 demonstrated Effect ENhance exhibit IMPROVE Inflammatory response inhibit Ivermectin lung lung tissue Lungs plasma concentration PLGA PLGA nanoparticle progression provide RBC-hitchhiking RBCs recent Red SARS-CoV-2 significantly treat Treatment virus was used [DOI] 10.1016/j.ijpharm.2022.121719 PMC 바로가기 [Article Type] Article
Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment잠재적인 COVID-19 치료제로서 생쥐에서 흡입된 이버멕틴의 약동학 및 안전성Article Published on 2022-05-102022-09-11 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 치료법, 치료제, [키워드] administration analyzed Antiviral antiviral efficacy BALB/c mice BALF binding Bronchoalveolar lavage fluid clinically collected Concentration concentrations COVID-19 Critical drug Dry Dry powder aerosol Formulation healthy histological in vitro in vitro experiment Inhalable ivermectin inhalation Inhaled intratracheal administration investigated Ivermectin kidney Lactose less limit limitation liver Local low dose lung Lungs mice Mild overcome pharmacokinetic pharmacokinetics plasma Protein Protein binding resolved respiratory tract Safety SARS-CoV-2 spleen spray Spray drying therapeutic Toxicity Treatment viral pathology was used [DOI] 10.1016/j.ijpharm.2022.121688 PMC 바로가기 [Article Type] Article
Effect of Early Treatment with Ivermectin among Patients with Covid-19Covid-19 환자에서 Ivermectin의 조기 치료 효과Randomized Controlled Trial Published on 2022-05-052022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, [키워드] acute respiratory syndrome Adaptive platform trial Admission adverse events Analysis assigned Bayesian credible interval Brazil caused clinics conducted coronavirus coronavirus disease defined Disease progression dose double-blind early diagnosis Effect Efficacy events finding hospital Hospital admissions Hospitalization incidence Intervention involved Ivermectin ivermectin group modified intention-to-treat no significant effect observation outcome Outpatient Patient patients per-protocol analysis Placebo placebo-controlled primary analysis progression public health randomization Randomized Randomly receive recruited regimen reported risk risk factor SARS-CoV-2 secondary outcome Symptom symptomatic the disease the placebo group Trial worsening [DOI] 10.1056/NEJMoa2115869 PMC 바로가기 [Article Type] Randomized Controlled Trial
Retraction notice to “Use of ivermectin in the treatment of Covid-19: A pilot trial” [Toxicol. Rep. 8 (2021) 505–510]Erratum Published on 2022-05-022022-10-05 Journal: Toxicology Reports [Category] 유전자 메커니즘, [키워드] Ivermectin Retraction Treatment [DOI] 10.1016/j.toxrep.2022.04.009 [Article Type] Erratum
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?COVID-19와 소분자 치료제의 약속: 배워야 할 교훈이 있습니까?Review Published on 2022-05-012022-09-11 Journal: Pharmacological research [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant therapy Antiviral antiviral agent Antiviral agents antivirals Baricitinib Baricitinib (PubChem CID: 44205240) Chloroquine Chloroquine (PubChem CID: 2719) coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical developmental Dexamethasone Dexamethasone (PubChem CID: 5743) drug Drug discovery effective Endemic Healthcare professional healthcare professionals Hydroxychloroquine Hydroxychloroquine (PubChem CID: 3652) Inclusion Ivermectin Ivermectin (PubChem CID: 6321424) limitation Lopinavir Lopinavir (PubChem CID: 92727) molnupiravir Molnupiravir (Pubchem CID: 145996610) Nirmatrelvir Nirmatrelvir (PubChem CID: 155903259) pandemic provided PubChem Remdesivir Remdesivir (PubChem CID: 121304016) researcher Retrospective analysis Ritonavir Ritonavir (PubChem CID: 392622) SARS-CoV-2 severe acute respiratory syndrome Coronavirus small molecule Small molecule therapeutics. standstill tested the disease therapy Treatment treatment of COVID-19 while with COVID-19 [DOI] 10.1016/j.phrs.2022.106201 PMC 바로가기 [Article Type] Review
Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infectionReview article Published on 2022-05-012022-10-05 Journal: Journal of trace elements in medicine and biology [Category] 신약개발, 치료제, [키워드] administration Antiviral antiviral drugs Chloroquine COVID-19 COVID-19 infection effective Endemic fatality help Hydroxychloroquine improvement Infection Ivermectin lower risk outcome Prophylaxis reduce reduce mortality risk risk of COVID-19 Safe Support Therapies therapy Treatment treatments of COVID-19 vaccination variant while with COVID-19 Zinc [DOI] 10.1016/j.jtemb.2022.126954 [Article Type] Review article
Pharmacological interventions to prevent Covid-19 disease: A rapid reviewCovid-19 질병을 예방하기 위한 약리학적 개입: 신속한 검토Review Published on 2022-05-012022-09-12 Journal: Reviews in Medical Virology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] article certainty of evidence Combination coronavirus coronavirus disease COVID-19 determine drug intervention Effectiveness high quality evidence high risk incidence Intervention Ivermectin monoclonal antibody peer-reviewed pharmacological intervention Placebo Prevent prevention Prophylaxis protective effect randomised controlled trial RCT RCTs reduce reduced reported risk of bia Risk of bias SARS-CoV-2 SARS-COV-2 infection Severity of disease significantly Support symptomatic and asymptomatic symptomatic disease tested Trial Vaccines Viral load while [DOI] 10.1002/rmv.2299 PMC 바로가기 [Article Type] Review
Ivermectin in COVID-19: The Case for a Moratorium on PrescriptionsArticle Published on 2022-05-012023-07-08 Journal: Therapeutic innovation & regulatory science [Category] COVID19(2023년), [키워드] COVID-19 Ivermectin Prescription moratorium randomized trials Regulatory science Therapeutic innovation. [DOI] 10.1007/s43441-022-00378-0 PMC 바로가기
Ivermectin: a mini-reviewReview Published on 2022-05-012023-07-08 Journal: Clinical toxicology (Philadelphia, Pa.) [Category] COVID19(2023년), [키워드] Avermectin COVID-19 Ivermectin P-glycoprotein poisoning [DOI] 10.1080/15563650.2022.2043338 [Article Type] Review
Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraudCOVID-19 예방을 위한 Ivermectin: 잠재적 편견 및 의료 사기 해결Meta-Analysis Published on 2022-04-272022-09-11 Journal: Journal of Antimicrobial Chemotherapy [Category] 임상, [키워드] Analysis antiparasitic drug clinical trial clinical trials conducted COVID-19 COVID-19 infection high risk investigated Ivermectin measure Meta-analysis multi-arm poor quality post-hoc analysis prevention of COVID-19 Primary outcome Quality Randomized controlled trial Randomized controlled trials randomized trial raw data risk of bia RoB 2 RT-PCR secondary outcome significant effect subgroup analysis symptomatic symptomatic COVID-19 Trial trials [DOI] 10.1093/jac/dkac052 PMC 바로가기 [Article Type] Meta-Analysis